UNASSIGNED: 4064 Background: Two regimen sequences: @entity4181 , @entity1487 (FU), and @entity2600 (mFOLFIRI) followed by @entity4181 , FU, and @entity901 (mFOLFOX7; arm A), or mFOLFOX7 followed by mFOLFIRI (arm B) were evaluated for their anti- @entity5 activity and @entity137 in Chinese @entity1 (pts) with locally advanced and metastatic @entity356 . METHODS: Previously untreated pts with gastric or gastro-esophageal junction @entity420 were randomized (1:1) to above two regimen sequences, as described in ASCO 2010 (TPS207). RESULTS: 145 pts, 71 in arm A and 74 in arm B, were included between April 2008 and September 2010. Demographic characteristics were comparable (arm A vs arm B), age: 53 vs 52; M/F: 71%/29% vs 73%/27%; PS 0-1: 52% vs 53%; metastatic: 92% vs 91%; @entity5 resected: 69% vs 66%. All the pts received at least one cycle in 1st line. The 1st-line treatments were well tolerated in both arms without treatment-related @entity204 . National @entity5 Institute Common @entity137 Criteria grade 3-4 @entity1398 (34%) and grade 3 @entity16 (12%) were more frequent with mFOLFOX7. However, pts in mFOLFIRI group experienced more grade 3 delayed @entity294 (6%) and grade 2 @entity1665 (45%). Other frequently reported adverse events were predominantly grade1 or 2, included @entity882 , @entity417 , @entity390 , @entity448 , @entity1295 , stomachache, @entity33 , and liver function abnormalities, without difference between two arms. 32% and 34%, in arm A and arm B, respectively, of chemotherapies were delayed because of @entity137 . Dose reduction was reported in 14 cases in arm A and 6 cases in arm B. CONCLUSIONS: Both regimens were well-tolerated with acceptable and manageable @entity137 . The first-line therapy efficacy is being followed up and will be presented at the meeting.

Preliminary results of a randomized phase II study: Treatment of Chinese @entity1 with advanced XXXX with FOLFIRI followed by FOLFOX7 or the reverse sequence.

@entity4181 :: ('MESH:D002955', 'Chemical') :: ['folinic acid'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity', 'toxicities', 'toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor', 'Cancer'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity16 :: ('MESH:D009422', 'Disease') :: ['sensory neuropathy'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
